Alemtuzumab (Campath)
Showing 1 - 25 of 329
Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)
Completed
- Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Campath
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)
Completed
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Alemtuzumab (Campath)
- EPOCH
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022
Predict T Cell Chimerism After MSD SCT for SCD?
Recruiting
- Sickle Cell Disease
- Alemtuzumab Injection [Campath]
-
Amsterdam, NetherlandsAmsterdam Medical Centre
Jun 20, 2023
Allogeneic Hematopoietic Cell Transplantation Trial (Alemtuzumab)
Not yet recruiting
- Allogeneic Hematopoietic Cell Transplantation
- (no location specified)
Aug 12, 2022
Sickle Cell Disease Trial in Hackensack (Alemtuzumab, Fludarabine, Melphalan)
Active, not recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Hackensack, New JerseyHackensack University Medical Center
Feb 4, 2022
Hemophagocytic Lymphohistiocytosis (HLH) Trial in Paris (Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA))
Completed
- Hemophagocytic Lymphohistiocytosis (HLH)
- Alemtuzumab
- +2 more
-
Paris, FranceHôpital Necker-Enfants Malades
Apr 13, 2021
Leukemia Trial in Houston (Alemtuzumab, Etoposide, Dexamethasone)
Active, not recruiting
- Leukemia
- Alemtuzumab
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 2, 2022
Sickle Cell Disease Trial in Duarte (drug, procedure, radiation)
Recruiting
- Sickle Cell Disease
- Alemtuzumab
- +3 more
-
Duarte, CaliforniaCity of Hope Comprehensive Cancer Center
Jul 31, 2022
Sickle Cell Anemia Trial run by the NHLBI (PBSC Transplant, Alemtuzumab, Sirolimus)
Active, not recruiting
- Sickle Cell Anemia
- PBSC Transplant
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022
Sickle Cell Disease, Beta Thalassemia-Major Trial in New Hyde Park (alemtuzumab (Campath IH), Fludarabine, Melphalan)
Completed
- Sickle Cell Disease
- Beta Thalassemia-Major
- alemtuzumab (Campath IH)
- +6 more
-
New Hyde Park, New YorkCohen Children's Medical Center of New York
Jul 30, 2021
T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), Peripheral T-Cell Lymphoma (PTCL) Trial run by the NCI (IL-15 plus,
Completed
- T-Cell Lymphoma Relapsed
- +4 more
- IL-15 plus
- alemtuzumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 27, 2022
Kidney Transplantation, Kidney Diseases, Kidney Failure Trial in London (Campath, Daclizumab)
Completed
- Kidney Transplantation
- +2 more
-
London, United KingdomWest London Renal and Transplant Centre, 4th Floor Ham House, Ha
Sep 1, 2021
Leukemia Trial in Chicago (Alemtuzumab, Rituximab)
Completed
- Leukemia
- Alemtuzumab
- Rituximab
-
Chicago, IllinoisNorthwestern University, Northwestern Medical Faculty Foundation
Oct 15, 2020
Aplastic Anemia Trial run by the NHLBI (Campath-1H, r-ATG, CsA)
Completed
- Aplastic Anemia
- Campath-1H
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jul 2, 2021
Sickle Cell Disease Trial in Chicago (Allogeneic Non-Myeloablative Stem Cell Transplantation, Alemtuzumab, Sirolimus)
Recruiting
- Sickle Cell Disease
- Allogeneic Non-Myeloablative Stem Cell Transplantation
- +2 more
-
Chicago, IllinoisUniversity of Illinois at Chicago
Feb 16, 2022
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure Trial in Baltimore (Alemtuzumab, Fludarabine,
Recruiting
- Primary Immune Deficiency Disorder
- +2 more
- Alemtuzumab
- +6 more
-
Baltimore, MarylandJohns Hopkins University
Oct 20, 2022
Severe Aplastic Anemia, Refractory, Severe Aplastic Anemia, Relapse Trial run by the NHLBI (Alemtuzumab (Campath ),
Completed
- Severe Aplastic Anemia, Refractory
- Severe Aplastic Anemia, Relapse
- Alemtuzumab (Campath )
- Cyclosporine
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jun 29, 2020
Sickle Cell Disease Trial in Saint Louis (drug, radiation, procedure)
Terminated
- Sickle Cell Disease
- Alemtuzumab
- +6 more
-
Saint Louis, MissouriWashington University School of Medicine
Jan 28, 2022
Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia Trial
Completed
- Acute Undifferentiated Leukemia
- +13 more
- allopurinol
- +16 more
-
Chicago, IllinoisCancer and Leukemia Group B
Apr 5, 2022
Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia Trial in Pittsburgh (CD3/CD19 depleted leukocytes, CD45RA
Recruiting
- Sickle Cell Anemia
- +2 more
- CD3/CD19 depleted leukocytes
- +6 more
-
Pittsburgh, PennsylvaniaChildren's Hospital of Pittsburgh of UPMC
May 4, 2022
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- alemtuzumab
- +2 more
-
Chicago, Illinois
- +1 more
Dec 29, 2020
Idiopathic Pulmonary Fibrosis, Emphysema or COPD Trial in Pittsburgh (CD3/CD19 negative hematopoietic stem cells, Rituximab,
Recruiting
- Idiopathic Pulmonary Fibrosis
- Emphysema or COPD
- CD3/CD19 negative hematopoietic stem cells
- +6 more
-
Pittsburgh, Pennsylvania
- +1 more
Feb 9, 2022
Sickle Cell Disease, Beta Thalassemia Trial in New York (Busulfan, Fludarabine, Alemtuzumab)
Active, not recruiting
- Sickle Cell Disease
- Beta Thalassemia
- Busulfan
- +3 more
-
New York, New YorkMorgan Stanley Children's Hospital, New York-Presbyterian, Colum
Aug 12, 2021
Crohn's Disease Trial in Pittsburgh (autologous CD34-selected peripheral blood stem cells transplant, Alemtuzumab, ATG)
Recruiting
- Crohn's Disease
- autologous CD34-selected peripheral blood stem cells transplant
- +8 more
-
Pittsburgh, Pennsylvania
- +1 more
Feb 9, 2022